INmune Bio, Inc. (INMB)

INmune Bio, Inc.'s stock price has declined significantly over the past six months. In December 2025, a price target was decreased, and the company published a study on its CORDStrom platform and announced new neuroimaging data. In October 2025, the company announced its Third Quarter results and provided a business update. In June 2025, the company announced it would present top-line data from its Phase 2 MINDFuL trial, leading to significant stock volatility. In May 2025, the company announced its First Quarter results and provided a business update.

Analysis suggests some seasonal tendencies for INmune Bio's stock. The company's stock has shown a historical seasonal strength period from approximately April 8 to July 14, resulting in a geometric average return of 68.32% above the S&P 500 Total Return Index over the past five years. This seasonal timeframe has outperformed the relative buy-and-hold performance of the stock by an average of 84.33% per year in four out of five periods.

INmune Bio, Inc. is a clinical-stage immunology company focused on developing immunotherapies that reprogram the innate immune system to treat diseases like cancer and neurodegenerative conditions. Their product pipeline includes the DN-TNF platform featuring XPro1595 for Alzheimer's and depression, the Natural Killer Cell Priming Platform with INKMUNE for cancer, and the CORDStrom™ platform for recessive dystrophic epidermolysis bullosa (RDEB), with plans to submit a BLA to the FDA in early 2026.

INmune Bio, Inc. is headquartered in Boca Raton, Florida, and has a presence in San Diego, California. Its clinical programs involve trial sites across North America.

INmune Bio has a consensus rating of "Hold" from analysts, with an average rating score of 2.29. The company has been the subject of scrutiny and speculation, particularly concerning its Alzheimer's disease trial. The stock price fluctuations around the Phase 2 MINDFuL trial data announcement reflect a reactive market sentiment. Shareholders have experienced dilution, with total shares outstanding growing by 19.9%.

The ownership structure of INmune Bio is a mix of institutional, retail, and individual investors. Institutional ownership is approximately 12.72% to 17.9%, with major holders including BlackRock, Inc. and Vanguard Group Inc. Individual insiders hold approximately 17% to 21% of the stock, including Raymond Tesi and Mark Lowdell. The general public and retail investors hold a significant portion, estimated to be around 59.6% to 77.38% of the shares.